Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.
“We will be filing within the next few days in the U.S.,” Erck told Yahoo Finance Live on Tuesday.
The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.
Novavax has now received four emergency use approvals,…
Source link
